Adaptimmune Therapeutics PLC: Nasdaq/NYSE listing notice — Adaptimmune receives Nasdaq delisting notice due to low bid price; intends to request hearing

Adaptimmune Therapeutics PLC

Nasdaq determined ADAP's closing bid price was $0.10 or less for 10 consecutive trading days as of Aug 12, 2025.
Company is subject to delisting under Low Priced Stocks Rule unless it requests a hearing; it intends to do so.
Delisting action stayed pending hearing and any extension granted by Nasdaq Hearings Panel; ADSs continue trading.
Company previously had until Oct 27, 2025 to regain $1.00 bid compliance; new rule triggers separate delisting process.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Adaptimmune Therapeutics PLC received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5810(c)(3)(A)(iii)

Exact text from the filing

August 14, 2025, Nasdaq issued a letter to the Company that as of August 12, 2025, it determined that the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule” together with the Rule, the “Rules”) and its securities are subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). Accordingly, the Company intends to timely request a hearing and therefore ex

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-25-011579

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.